0UNL Stock Chart & Stats
$69.52
$0.08(0.12%)
At close: 4:00 PM EDT
$69.52
$0.08(0.12%)
Day’s Range― - ―
52-Week Range$25.10 - $109.01
Previous CloseN/A
Volume20.00
Average Volume (3M)1.16K
Market Cap
$2.57B
Enterprise Value$1.76K
Total Cash (Recent Filing)$684.34M
Total Debt (Recent Filing)$78.56M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Nov 05, 2026EPS Estimate
-2.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.61
Shares Outstanding33,786,034
10 Day Avg. Volume818
30 Day Avg. Volume1,157
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)7.94
Price to Sales (P/S)12.91
P/FCF Ratio-3.42
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$156.50Price Target Upside125.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-8.95
Revenue Forecast (FY)$41.41M
Bulls Say, Bears Say
Bulls Say
Clear Phase III Development PathA clearly defined Phase III program with target start dates, readouts and a BLA timeline materially reduces development execution uncertainty. This allows management to allocate resources, sequence CRO/site work, and plan commercial preparations well ahead, strengthening long-term program credibility and partnerability.
Strong Pro Forma Liquidity And RunwayA >$1B cash position and runway into Q3 2028 provide durable funding to initiate and advance global Phase III programs without immediate dilution. This liquidity supports multi-year trial execution, patient enrollment, and partner negotiations, lowering near-term financing risk and enabling strategic optionality through pivotal stages.
Differentiated Mechanism And Favorable SafetyA distinct Treg‑stimulating MOA and a favorable safety profile versus JAKs constitute a sustainable competitive advantage for chronic indications. Fewer monitoring constraints and improved tolerability can expand prescriber acceptance, support broader label positioning, and sustain long‑term market share if efficacy is confirmed in pivotal trials.
Bears Say
Persistent High Cash BurnConsistent negative operating and free cash flow (~-$204M TTM) means the company will continue to rely on financing or existing reserves to fund development. Even with current cash, sustained burn through Phase III increases dilution risk over time and constrains flexibility for opportunistic investments or faster commercialization.
Large Ongoing Operating And Net LossesDeep negative margins reflect structural unprofitability absent product revenue. Persistent operating losses depress return potential for shareholders, can limit reinvestment capacity, and make future financing terms more dilutive or costly, especially if pivotal trials extend timelines or require additional studies to meet regulators' expectations.
Regulatory And Trial Execution RiskOutstanding regulatory design questions for alopecia areata and the logistical complexity of ~150‑site global Phase IIIs create durable execution risk. Misalignment on endpoints or slow enrollment can delay approvals, increase spend, and potentially require additional trials, materially impacting timelines and commercial prospects.
Nektar Therapeutics News
0UNL FAQ
What was Nektar Therapeutics’s price range in the past 12 months?
Nektar Therapeutics lowest share price was $25.10 and its highest was $109.01 in the past 12 months.
What is Nektar Therapeutics’s market cap?
Nektar Therapeutics’s market cap is $2.57B.
When is Nektar Therapeutics’s upcoming earnings report date?
Nektar Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 83 days.
How were Nektar Therapeutics’s earnings last quarter?
Nektar Therapeutics released its earnings results on Aug 13, 2026. The company reported -$1.23 earnings per share for the quarter, beating the consensus estimate of -$1.971 by $0.741.
Is Nektar Therapeutics overvalued?
According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued.
Does Nektar Therapeutics pay dividends?
Nektar Therapeutics pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Nektar Therapeutics dividends here
What is Nektar Therapeutics’s EPS estimate?
Nektar Therapeutics’s EPS estimate is -2.14.
How many shares outstanding does Nektar Therapeutics have?
Nektar Therapeutics has 33,786,034 shares outstanding.
What happened to Nektar Therapeutics’s price movement after its last earnings report?
Nektar Therapeutics reported an EPS of -$1.23 in its last earnings report, beating expectations of -$1.971. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Nektar Therapeutics?
Currently, no hedge funds are holding shares in GB:0UNL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nektar Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$156.50 (125.12% Upside)
$156.50 (125.12% Upside)
Blogger Sentiment
Bullish
GB:0UNL Sentiment 91%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $42.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
187.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
197.87%
Trailing 12-Months
Company Description
Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
0UNL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call contained multiple substantial positive developments: initiation of the global Phase 3 program in atopic dermatitis, FDA-aligned registrational design for alopecia areata, strong Phase 2b signals (efficacy, durability, favorable safety), robust cash balance after a $350M offering, and encouraging market research supporting commercial potential. Offsetting these positives are expected higher R&D and G&A spend, a meaningful quarterly net loss, modest near-term revenue largely from non-cash royalties, a cash runway that covers key mid-2028 readouts but leaves limited buffer for delays, and an ongoing litigation matter. On balance the strategic, clinical, and financial highlights outweigh the risks described on the call.View all GB:0UNL earnings summaries0UNL Stock 12 Month Forecast
Average Price Target
$156.50
▲(125.12% Upside)
Technical Analysis
Wave Life Sciences
―
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―